Zacks Investment Research upgraded shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning. Zacks Investment Research currently has $9.25 price target on the biotechnology company’s stock.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

NBRV has been the topic of several other reports. Cantor Fitzgerald reiterated a buy rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a research note on Friday, September 1st. SunTrust Banks, Inc. initiated coverage on Nabriva Therapeutics AG in a research note on Friday, August 25th. They set a buy rating and a $20.00 target price on the stock. ValuEngine upgraded Nabriva Therapeutics AG from a sell rating to a hold rating in a research note on Saturday, June 24th. Needham & Company LLC reiterated a buy rating and set a $18.00 target price (up from $15.00) on shares of Nabriva Therapeutics AG in a research note on Tuesday, September 19th. Finally, HC Wainwright reiterated a buy rating and set a $18.00 target price (up from $16.00) on shares of Nabriva Therapeutics AG in a research note on Monday, August 28th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The stock has an average rating of Buy and an average target price of $18.78.

Nabriva Therapeutics AG (NBRV) traded down 2.51% on Wednesday, hitting $7.38. The stock had a trading volume of 557,220 shares. The company’s market cap is $198.06 million. The stock has a 50 day moving average price of $8.37 and a 200 day moving average price of $9.78. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $14.10.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.34 million. On average, equities research analysts expect that Nabriva Therapeutics AG will post ($2.29) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/nabriva-therapeutics-ag-nbrv-lifted-to-buy-at-zacks-investment-research/1631094.html.

In other news, major shareholder Hbm Healthcare Investments (Ca sold 6,585 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $10.51, for a total transaction of $69,208.35. Following the transaction, the insider now directly owns 2,391,177 shares of the company’s stock, valued at approximately $25,131,270.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Vivo Capital Viii, Llc purchased 52,631 shares of the stock in a transaction dated Monday, September 18th. The shares were purchased at an average cost of $9.46 per share, for a total transaction of $497,889.26. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 57,219 shares of company stock worth $535,919 and have sold 195,670 shares worth $1,983,641. 2.75% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBRV. Wellington Management Group LLP lifted its holdings in shares of Nabriva Therapeutics AG by 9.9% during the 1st quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Almanack Investment Partners LLC. bought a new position in Nabriva Therapeutics AG in the 1st quarter worth $1,870,000. Nationwide Fund Advisors raised its holdings in Nabriva Therapeutics AG by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after purchasing an additional 7,924 shares during the period. Finally, Royal Bank of Canada raised its holdings in Nabriva Therapeutics AG by 19.6% in the 2nd quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares during the period. 50.23% of the stock is currently owned by hedge funds and other institutional investors.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with Analyst Ratings Network's FREE daily email newsletter.